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Abstract
Background: Publicly available data repositories facilitate the sharing of an ever-increasing amount
of microarray data. However, these datasets remain highly underutilized. Reutilizing the data could
offer insights into questions and diseases entirely distinct from those considered in the original
experimental design.
Methods: We first analyzed microarray datasets derived from known perturbations of specific
pathways using the samr package in R to identify specific patterns of change in gene expression. We
refer to these pattern of gene expression alteration as a "pathway signatures." We then used
Spearman's rank correlation coefficient, a non-parametric measure of correlation, to determine
similarities between pathway signatures and disease profiles, and permutation analysis to evaluate
false discovery rate. This enabled detection of statistically significant similarity between these
pathway signatures and corresponding changes observed in human disease. Finally, we evaluated
pathway activation, as indicated by correlation with the pathway signature, as a risk factor for poor
prognosis using multiple unrelated, publicly available datasets.
Results:  We have developed a novel method, Expression-based Pathway Signature Analysis
(EPSA). We demonstrate that ESPA is a rigorous computational approach for statistically evaluating
the degree of similarity between highly disparate sources of microarray expression data. We also
show how EPSA can be used in a number of cases to stratify patients with differential disease
prognosis. EPSA can be applied to many different types of datasets in spite of different platforms,
different experimental designs, and different species. Applying this method can yield new insights
into human disease progression.
Conclusion: EPSA enables the use of publicly available data for an entirely new, translational
purpose to enable the identification of potential pathways of dysregulation in human disease, as well
as potential leads for therapeutic molecular targets.
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Background
Publicly available data repositories facilitate the sharing of
an ever-increasing amount of microarray data. However,
the datasets in these repositories typically remain highly
underutilized following the analysis for which they were
originally intended. This situation is unfortunate because
reusing the data can offer insights into pathways and dis-
eases entirely distinct from those considered in original
experimental designs.
In order to take full advantage of the data in the public
domain, new ways of using and integrating the informa-
tion will be required. To meet this need, we have devel-
oped a statistical method for pattern matching between
highly disparate sources of data. Our approach compares
gene expression alterations in human disease with expres-
sion patterns in publicly available collections, or compen-
dia, of microarray data. These datasets contain
information on changes in gene expression in response to
perturbations of cells, such as stimulation with a small
molecule or alterations due to a transgenic mutation. If
similarities can be detected between the changes in gene
expression in diseased versus normal tissues, and those
changes observed by perturbing known pathways, these
observations may provide new information regarding
pathways that are potentially affected in disease. They also
provide new insights into human disease and possible
therapeutic interventions. Specifically, our method is use-
ful for hypothesis generation in two important areas: (i)
identifying pathways undergoing dysregulation in dis-
ease; and (ii) relating pathway activation to clinically rel-
evant observations.
Although there are many knowledge-based resources (e.g.
GO, the Gene Ontology) that can be used to determine
the significance of genomic findings, relatively few inves-
tigators have pursued a data-driven approach for generat-
ing clinical or mechanistic hypotheses. Bild et al. used
supervised machine learning classifiers to calculate a
probability score for the presence or absence of specific
oncogenic mutations [1]. The study showed that cluster-
ing patients by probability score across multiple muta-
tions identified groups with significantly divergent
prognoses. Crucial to the success of this approach was a
strong expression signal and a sufficient number of repli-
cates from which the classifier could learn. Unfortunately,
machine learning algorithms are known to over-fit when
given sparse training data, which is often the case with
microarray experiments [2].
Recognizing that a novel approach was needed for pattern
matching among noisy and disparate datasets, Lamb et al.
created the Connectivity Map, which compares a query
signature to a compendium of expression profiles using a
non-parametric approach [3]. The main weakness to this
approach is that it lacks a statistical method for determin-
ing the significance of observed connections.
An important question is whether a data-driven approach
can use knowledge gained in the analysis of one dataset to
aid the analysis of other microarray data. To address this
question, we developed a method for finding similarity
between disparate and noisy gene expression datasets. The
method also calculates the statistical significance of its
results. We applied it by comparing gene expression pro-
files from samples of human disease with profiles gener-
ated by known perturbations to cells. Our work shows
that the method is robust to noise, sparse data, and miss-
ing values, and can use data from different microarray
platforms and non-human species to draw conclusions
about human disease. Our method is better at differenti-
ating prognosis based on individual pathway activation
than the approach employed by Bild et al. for a human
ovarian cancer dataset. In addition, we show that our
method can be applied to a small-molecule perturbation
dataset to suggest potential therapeutic leads. Finally, we
demonstrate that the method may be applied even across
datasets from divergent species to yield findings that are
suggestive of target pathways for therapeutic intervention.
Results
We used a robust, non-parametric measure of correlation
to develop a general statistical method for reusing pub-
licly available microarray data. The purpose of the
method is to generate clinically relevant hypotheses
regarding human disease. It employs the widely used SAM
software package to define "pathway signatures" from
known molecular perturbations [4]. The term "pathway
signature" refers to the specific pattern of differential gene
expression that was observed upon experimental pertur-
bation of a given pathway. It is represented by the log2 of
the fold change for the list of differentially expressed
genes in the perturbed versus the non-activated state.
Extracting this subset of genes is necessary in order to pin-
point the genes at play in the specific pathway of interest,
and to eliminate other factors such as cell type could dom-
inate any correlative signal detected. Our method can
then assess the degree of statistical similarity between
gene expression profiles in human disease and these path-
way signatures, which in turn can be used as a measure of
pathway activation. We are then able to evaluate pathway
activation as a risk factor for patient survival. We call this
approach Expression-based Pathway Signature Analysis
(EPSA). Figure 1 provides an overview of EPSA.
Application to existing, established datasets
EPSA correctly identifies pathway mutations in cancer data
Bild et al. trained Bayesian regression models on a train-
ing set derived from replicates of five different oncogenic
mutations. These predictors were able to assess the relativeBMC Medical Genomics 2008, 1:51 http://www.biomedcentral.com/1755-8794/1/51
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probability of pathway deregulation in tumors and cell
lines for these five affected pathways. The authors then
demonstrated that pathway prediction for positive control
samples tended to reflect the molecular basis for tumori-
genesis. This tendency was indicated by probability scores
derived from their method of regression analysis [1]. Pos-
itive controls were expression patterns from mammary
tumors from mice carrying transgenic copies of the onco-
genes used in the training set or, in the case of Rb null ani-
mals, knockouts of an inhibitor of E2F3 [5]. Figure 2A
shows results for positive controls presented by Bild et al.,
and Figure 2B shows results for a similar analysis using
EPSA correlation scores instead of a regression probability
score. EPSA demonstrates a similarly high level of accu-
racy in identifying the actual underlying mutation in pos-
itive controls.
EPSA prognosis prediction outperforms that of Bild et al.'s more 
complex machine learning approach
Figure 3 shows Kaplan-Meier survival curves for an ovar-
ian cancer patient cohort (n = 135). The curves are based
on EPSA correlation scores for each of the five oncogenic
mutations performed by Bild et al. (see Methods). They
show the two extreme tertiles of patients: namely, the
third of patients with the highest degree of correlation and
the third with the lowest degree of correlation. p-values
are provided for Cox proportional-hazards analysis across
all patients (described in Methods). These results may be
compared with those in Supplementary Figure 4 of the
Bild et al. paper. Mutations in the Myc and E2F3 pathways
are roughly comparable as factors influencing survival in
both methods. Mutations of the Ras and β-catenin path-
ways had low p-values in the EPSA and Bild analyses, but
neither were significant when corrected for multiple
hypothesis testing. Importantly, results of the Src pathway
using Bild's method were not significant when corrected
for multiple hypothesis testing (p = 0.22), while the p-
value generated using EPSA was highly significant at 0.002
after Bonferroni correction. One major finding of the
paper by Bild et al. was that clustering patients into six
groups based on all five mutations together gave a more
significant differential prognosis. Here, too, EPSA differ-
entiated survival to a statistically significant degree, (Kap-
lan-Meier p-value < 0.0093 [not shown]).
EPSA detects statistically lower correlation in disease profiles with 
Connectivity Map perturbagens
The Connectivity Map is a reference collection of expres-
sion profiles generated by stimulation of human cultured
cells with a number of small molecules, along with an
algorithmic method for data mining through pattern
matching. One goal of the approach was to detect func-
Methodology for application of EPSA Figure 1
Methodology for application of EPSA. A. For each perturbation in the training compendium, replicate log2 expression of 
treated vs. untreated cells were analyzed. B. For each perturbation, Significance Analysis of Microarrays (SAM) [4] software 
was applied to identify genes with significantly altered expression. Median values among the replicates of log2(treated/
untreated) were used to represent genes in a signature. C. These values were correlated with test profiles. A false discovery 
rate was calculated for each perturbation, for the average level of correlation with disease profiles. D. For those signatures 
with a statistically significant level of correlation, survival analysis was performed using the EPSA score, or the degree of signa-
ture correlation, as a factor influencing survival. Survival analysis was carried out using the survival package in R.
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Positive control validation for accuracy and specificity Figure 2
Positive control validation for accuracy and specificity. Gene expression profiles were used to compare accuracy and 
specificity of signatures from Bild's study (panel A, used with permission) and EPSA (panel B). The profiles were derived from 
mammary tumors in mice transgenic for the MMTV-MYC, MMTV-HRAS or MMTV-HER2 oncogenes, from murine tumors 
dependent on loss of Rb, or from seven samples of normal murine mammary tissue. The predicted probability of Myc, E2F3 
and Ras activity in these tumors was sorted from low (blue) to high (red), and displayed as a color bar. Both methods correctly 
ranked the appropriate test cases as highest scoring (whether probability or correlation) for the respective mutations. Myc 
gave the strongest signal in both methods, followed by Rb null and Ras, in that order. (Loss of Rb causes an increase in E2F3 
expression.)BMC Medical Genomics 2008, 1:51 http://www.biomedcentral.com/1755-8794/1/51
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Kaplan-Meier analysis for individual pathway activity as a factor for survival in ovarian cancer Figure 3
Kaplan-Meier analysis for individual pathway activity as a factor for survival in ovarian cancer. The patient cohort 
was from Bild et al. [1] Results from the Src pathway using Bild's method were not significant when corrected for multiple 
hypothesis testing (p = 0.04), while the p-value generated using EPSA and Cox proportional-hazards was highly significant (p = 
0.0004). Note that although the EPSA curves show only the extreme tertiles of subjects, Cox proportional-hazards analysis 
was performed across all subjects in order to be directly comparable with the results in Bild et al.
High correlation
Low correlation
Survival analysis for Connectivity Map perturbagen correlation as a risk factor Figure 4
Survival analysis for Connectivity Map perturbagen correlation as a risk factor. Kaplan-Meier survival curves repre-
sent the top and bottom tertiles of patients with respect to correlation with the perturbagen signature. Black curves represent 
patients with higher correlation with the perturbagen signature, while the gray curve represents a lower level of correlation.BMC Medical Genomics 2008, 1:51 http://www.biomedcentral.com/1755-8794/1/51
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tional connections between disease and drug action. Of
note, the authors showed that connections could be
detected even across cell types. Of the thirty-two Connec-
tivity Map perturbagens for which we were able to gener-
ate pathway signatures (see Methods), none showed a
significantly higher degree of correlation with tumor
expression profiles from the Bild et al. ovarian cancer
cohort than randomly permuted signatures. However,
twenty-one perturbagens showed significantly lower lev-
els of correlation with disease data [see Additional file 1].
That is, disease tissue profiles tended to show lower corre-
lation with the pathways activated by these perturbagens
than would be expected by random chance.
EPSA predicts differential prognosis in cancer patients based on 
projected activation level of small-molecule pathways
For the twenty-one molecules with a lower degree of cor-
relation with patient profiles from the ovarian cancer
cohort, we performed survival analysis using the degree of
correlation between the signature and the tumor expres-
sion profile as a factor influencing survival. After Bonfer-
roni correction, five of the perturbagen signature
correlation values were determined to be significant fac-
tors influencing survival. The directionality of the effect
for two of them (LY294002 and Trichostatin Aa) was
opposite to what would be intuitive or helpful therapeuti-
cally, but of particular interest were results for the remain-
ing three compounds: monorden, 17-allylamino-
geldanamycin (17AAG), and ikarugamycin (Cox propor-
tional analysis p-values: 2 × 10-4, 3 × 10-6, and 3 × 10-8
respectively; Figure 4). For these drugs, lower correlation
with the drug signature corresponded to a lower rate of
survival. Higher correlation with the drug signature corre-
sponded to a higher rate of survival, though paradoxically,
this higher correlation is also closer to the average
expected correlation between the patient samples and the
pathway signature. These results suggest that, for any one
of these three small molecules, the corresponding path-
way may be dysregulated in ovarian cancer, and that treat-
ment with the drug could induce a beneficial drug
signature. Of course, additional experiments would be
required to tease out the actual underlying molecular
mechanisms, and whether this proposed explanation
would in fact play out with actual stimulation of ovarian
tumor cells using these known therapeutic molecules.
Application to a divergent species dataset
Pathway signature determination from compendium data
Based on clinical relevance and availability of outcome
data, we chose B cells as a model cell on which to test our
approach. Gene Expression Omnibus series GSE2050 pro-
vides time course data in which gene expression profiles
from mouse B cells stimulated with 33 different ligands
were compared to gene expression profiles of unstimu-
lated B cells [6,7]. We used this data as the training com-
pendium for EPSA. We used SAM [4] to identify pathway
signatures of differentially expressed genes for each of the
33 ligands in the compendium dataset. We then sought to
confirm that these pathway signatures would show a sta-
tistically significant degree of correlation with profiles
generated through activation of the same pathways in
other experiments, and on other microarray platforms.
EPSA identifies correlation patterns in positive controls from mouse 
B cells
GEO dataset GSE1014 (no associated PubMed ID) was
generated by stimulating mouse B cells with a subset of
ligands that had also been used in GSE2050. We used it as
a positive control to confirm that correlations between
test set profiles and corresponding ligand signatures
derived from the compendium were detectable and differ-
entiable. The resulting correlations, averaged among test
replicates, are shown in Additional file 2A. In three out of
the four test cases, the ligand used to stimulate the cells in
the test set was correctly re-identified as the most highly
correlated compendium profile. One test stimulation,
lipopolysaccharide (LPS), was misidentified as CD40 lig-
and (CD40L), but LPS was a close second. In summary,
our method demonstrated good sensitivity for detecting
similarity between test profiles in mouse B cells and corre-
sponding profiles derived from the mouse B cell compen-
dium data.
EPSA detects correlation patterns in positive controls from human B 
cells
Applying our method to human B cells introduced addi-
tional complexity, in that the genes from the compen-
dium mouse arrays had to be translated to their human
orthologs and then translated again to the probes used on
the human array platform. This was accomplished with
NCBI's HomoloGene mapping (see Methods for details).
Our method was designed to account for the fact that
many genes might not be translated because of platform
differences or a lack of orthologs. Note that these datasets
were generated in an independent laboratory. All four
stimulations in human B cells included Anti-Ig (AIG), and
correlation with the AIG pathway signature for all four
samples was high [see Additional file 2B]. In addition,
CD40L correlation was high for the first two samples,
which included CD40L, but lower for the second two
samples, which did not include it. With the exception of
IL4 stimulation in one sample, which did not demon-
strate high correlation with the IL4 compendium profile,
these results show that our method has good (though not
perfect) sensitivity for detecting similarities between pro-
files, even when comparing across platform and species,
and at different time points. Potential reasons for not
detecting IL4 include one-time experimental or biological
variability, since the test case represented only a single
microarray. Interestingly, the next sequentially labeledBMC Medical Genomics 2008, 1:51 http://www.biomedcentral.com/1755-8794/1/51
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experiment in the series in theory applied only AIG, but
this array did show a higher degree of correlation with IL4.
Without replicates, human error in the form of mislabe-
ling cannot be ruled out.
Application of EPSA to diffuse large B cell lymphoma on cDNA 
microarrays
Having confirmed a reasonable level of sensitivity for cor-
relation detection in positive controls, we next applied
EPSA to microarray data from human samples of diffuse
large B cell lymphoma (DLBCL), a B cell malignancy. The
goal was to determine which pathways, if any, are acti-
vated in this disease, and if their activation has implica-
tions for survival. Using a dataset comprising gene
expression profiles from 240 DLBCL patients [8], a
number of the compendium ligands showed positive cor-
relation with disease profiles [see Additional file 3].
To assess the significance of these correlations, we com-
puted a false discovery rate (FDR) through permutation
analysis (described in Methods). We identified four lig-
ands with significant q-values: AIG, CD40, CPG, and LPS,
with q-values of < 0.001, 0.08, 0.05, and 0.11 respectively
[see Additional file 4].
We next performed survival analysis on the cohort of
DLBCL patients using the level of correlation with the dif-
ferent signatures as factors influencing survival. The origi-
nal study used unsupervised hierarchical clustering to
group patients into three subtypes of DLBCL: germinal
center-like (GC), activated B cell-like (AB), and type III. Of
these subtypes, GC patients tended to have the best sur-
vival (p < 0.0001). AB and type III patients had poorer
prognoses, but were statistically indistinguishable from
each other using this methodology (Figure 5A).
We performed Cox proportional-hazards analysis on the
same data to evaluate the EPSA score for the four statisti-
cally significant ligands listed above as potential factors
influencing survival. Cox proportional-hazards analysis
showed that AIG correlation was not a significant factor
for survival, while the other three were significant, with
Bonferroni corrected p-values for LPS, CD40, and CPG of
0.004, 0.0008, and 0.004 respectively (Figure 5B, 5C, and
5D). Toll-like receptor 4 (TLR4), Toll-like receptor 9
(TLR9), and CD40 are the receptors to which LPS, CPG,
and CD40 ligand respectively bind to activate cells. There-
fore, statistically significant, positive correlations with a
signature found in TLR4, TLR9, and CD40 pathway activa-
tion were each associated with poor prognosis in diffuse
large B cell lymphoma. As discussed below, a number of
previous studies have demonstrated results that are in
keeping with these findings.
Even more interesting are the results when this analysis is
performed on activated B cell-like and type III, the two
disease subtypes that were indistinguishable in the origi-
nal study: Figure 5A shows that the AB and type III sub-
types are statistically indistinguishable (p  = 0.45). We
analyzed these subtypes only and grouped by level of cor-
relation (high, medium, or low) with pathway signatures
for LPS, CD40, or CPG as described above. The results
were the Kaplan-Meier curves shown in Figure 5B, 5C, and
5D. The curves represent the two extreme tertiles of
patients, or the highest versus lowest degree of correla-
tion. Cox proportional-hazards analysis across this entire
subset of patients yielded Bonferroni corrected p-values of
0.008, 0.001, and 0.004 respectively for LPS, CD40, and
CPG. The distinction being made is therefore independ-
ent from that of the GC, AB, type III system established in
the original study [8].
Discussion
We have presented a method that allows the use of pub-
licly available microarray data to gain insight into human
biology and disease. Our method can even be used on
datasets generated in a model organism. The method can
equal and even outperform more complex and labor-
intensive methods when applied to established data. Fur-
thermore, its results can be statistically validated through
calculation of false discovery rate. In one example shown
here, an existing dataset generated in order to gain insight
into pathways of activation in mouse B cells provided rel-
evant prior knowledge to facilitate novel insights and
hypothesis generation in human cancer. Using publicly
available microarray data from murine cells, we have
shown that a pattern of differential prognosis emerges
from assessment of similarity with known pathway signa-
tures. Moreover, this pattern is reproducible despite the
fact that test data were generated using entirely different
microarray platforms and species from those used in the
generation of training data. While this knowledge has
direct implications for difficult decisions regarding aggres-
sive therapeutic interventions in cancer treatment, the
method is generalizable to numerous other clinical
insights and discoveries. We assert that public biological
data repositories are a rich and largely untapped resource
for translational biomedical research.
Bild et al. demonstrated that pathway prediction in posi-
tive control samples, as indicated by probability scores,
tended to reflect the molecular basis for tumorigenesis.
Similarly, EPSA showed that pathway prediction for these
samples, as indicated by Spearman rank correlation, also
reflected underlying molecular mechanisms. Also consist-
ent between the two methods is the relative strength of
signal between the different mutations, with Myc most
easily distinguished by both, and Ras the least distinguish-
able. Applying EPSA to the dataset provided by Bild, et al.BMC Medical Genomics 2008, 1:51 http://www.biomedcentral.com/1755-8794/1/51
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yielded results that were comparable to the original
results, which came from more a specialized and involved
analysis.
With respect to application to the Connectivity Map data,
increased patient profile correlation with ikarugamycin,
17-allylamino-geldanamycin, and monorden all resulted
in better patient prognosis. Ikarugamycin is an antibiotic
that inhibits oxidized low-density lipoprotein uptake [9].
Kaplan-Meier survival analysis comparing results from Rosenwald and EPSA Figure 5
Kaplan-Meier survival analysis comparing results from Rosenwald and EPSA. A. Kaplan-Meier survival curve from 
Rosenwald, in which GC type diverges from the other subtypes (p < 0.0001), but AB and Type III do not diverge significantly (n 
= 240) [8]. B-D. Kaplan-Meier curves for activated B cell-like and type III DLBCL (n = 125) separated based on degree of cor-
relation with LPS, CD40, and CPG signatures respectively. Patients in these plots are only those in the lower two curves from 
A; the GC subtype was excluded from analysis. Survival curves for the most- and least-correlated tertiles (n = 125/3 ≈ 42 each) 
diverge significantly, in contrast to that of the AB vs. type III distinction. Cox proportional-hazards p-value is shown for the 
subset of the 125 AB and type III patients.
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It has also been implicated in the inhibition of clathrin-
coated pit mediated endocytosis [10]. A number of related
antibiotic compounds play a useful role in cancer therapy
[11,12]. More specifically, the macrolide class of antibiot-
ics, to which ikarugamycin belongs, can reverse drug
resistance in vitro and in vivo [13].
17-allylamino-geldanamycin (17AAG) and monorden are
both inhibitors of heat shock protein 90 (Hsp90) [14,15].
Hsp90 is a molecular chaperone that assists in stability
and function of various mutated or over-expressed pro-
teins responsible for tumor survival and growth. Hsp90
inhibition has shown promise in preclinical cancer stud-
ies [14]. Moreover, 17AAG has been an active subject of
clinical trials in recent years [16-20]. These findings sup-
port our results, which indicate that higher drug activity
levels for all of these compounds correspond to better
prognosis.
While there are multiple citations supporting our findings
for monorden and 17AAG [14-16,18,19,21], far fewer
studies promote ikarugamycin in the treatment of cancer.
As mentioned, the macrolide class of antibiotics has
shown promising effects in reversing drug resistance [13].
Based on these results, ikarugamycin and related com-
pounds may be promising leads as cancer therapeutics.
Further biological investigation is warranted.
Cancer and Toll-like receptors
Bacteria and inflammation due to microbial stimulation
of Toll-like receptors have been associated with carcino-
genesis and cancer progression [22-26]. Moreover, various
studies have shown a relationship between TLR4 activa-
tion (the receptor for LPS) and cancer progression [27,28].
The fact that this relationship is not present in some can-
cers, such as adenocarcinoma (EPSA data not shown)
indicates that it is not simply the case that inflammation
is associated with cancer progression. Rather, TLR path-
way activation appears to have a selective effect in specific
cancers. Future bench work will be to probe this hypothe-
sis in a biological system. As an immediate next step, we
aim to determine the activity of Toll-like receptors in
human diffuse large B cell lymphoma.
Beyond differential prognosis, our approach can provide
a starting point for analyzing functionally relevant genes.
A number of studies have attempted to define the smallest
number of genes that can be used to accurately predict
class membership or prognosis in cancer [29,30]. How-
ever, these gene sets were selected based on an ability to
discriminate between phenotypes, without prior knowl-
edge of gene function or pathway involvement. In con-
trast, genes in a pathway signature offer additional insight
regarding mechanism, since a possible cause of differen-
tial expression of those genes is known.
We evaluated a range of uniform q-value thresholds to use
in determining a pathway signature. A next step will be to
use varying thresholds, dependent on the relative degree
of perturbation promiscuity. In addition, our current
approach to false discovery rate is to compare random cor-
relations to the mean true correlation value. This method
tends to miss cases where different subpopulations fall at
different extreme ends of the spectrum, since correlation
values would be likely to regress to the mean neutral
value, easily observed by random chance. A more elegant
method with greater sensitivity would be preferable.
Finally, we plan to enhance and expand our methods for
determining pathway signatures by expanding the scope
of arrays on which we base a given profile, looking across
all of GEO for relevant studies.
Conclusion
In conclusion, we have demonstrated the ability to inte-
grate human disease data with publicly available genomic
data from experiments performed in humans and in
model organisms, even though the data had been gener-
ated to answer separate questions. This has enabled us to
generate testable hypotheses regarding pathway dysregu-
lation in human disease as well as its effects on patient
prognosis. This work demonstrates that we can use pub-
licly available data not only for asking questions about
pathways and interactions, but for immediate, clinically
relevant hypothesis generation.
Methods
Expression-based Pathway Signature Analysis (EPSA) 
implementation
The EPSA approach involves three main steps. They are
illustrated in Figure 1 and described in detail below: 1)
definition of pathway signatures from compendium data
(A-B); 2) calculation of mean correlations, r1 ... n, between
disease profiles and n pathway signatures, and the statisti-
cal significance thereof (B-C); and 3) survival analysis on
a patient dataset using each statistically significant r as a
risk factor (C-D). Unless otherwise specified, these steps
were implemented as scripts in R and microarray data was
processed as described by the original authors for each
respective dataset.
Pathway signatures were determined by applying the SAM
software package (samr package in R, version 1.20) to
publicly available microarray datasets [4]. Two-class
unpaired comparison was used for comparing activated or
treated samples with control samples. The designated
groups consisted of three or more replicates in all cases.
Sensitivity analysis using the Rosenwald DLBCL dataset
[8] showed that choice of q-value within a range of 0.01 to
0.1 did not significantly affect results. That is, varying the
threshold for false discovery rate and thus the number of
genes included in the signature did not alter downstreamBMC Medical Genomics 2008, 1:51 http://www.biomedcentral.com/1755-8794/1/51
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observations regarding which pathway signatures demon-
strated significant correlation, nor which signatures were
able to stratify prognosis (not shown). Therefore, a q-
value threshold for false discovery rate was chosen empir-
ically to include enough genes for statistically significant
results.
For the Bild dataset, replicate arrays from each of the five
mutation pathways were compared to control GFP-treated
tissue profiles. For the Connectivity Map profiles, treated
MCF7 cells were compared to untreated MCF7 cells.
MCF7 is a human breast adenocarcinoma cell line. We
generated pathway signatures using a subset of the 564
total profiles that met the following criteria: (i) Data were
generated in MCF7 cells. Although using additional cell
types would likely have resulted in a more generic, cell-
type-agnostic signature, the need for comparison to differ-
ent control cell types would have added complexity to the
analysis. (ii) At least three replicates were run at a single
concentration. Fewer replicates would be less likely to
yield reliable results. Finally, for the AfCS mouse B cell
dataset, treated versus untreated samples were compared
in triplicate and analyzed at the last time point (4 hours).
In all cases, for the genes determined to be statistically sig-
nificant by SAM, median values of log2(treated/untreated)
were used to represent the ligand signature.
The EPSA score for a ligand was the average correlation
between the ligand signature and the corresponding gene
expression values across the test profiles. This value was
determined using the Spearman rank order correlation
coefficient. In order to determine the statistical signifi-
cance of the resulting correlations, we calculated a q-value,
or false discovery rate, for the average level of correlation
between each ligand and the set of patients [31]. To do
this, a selection of n genes was chosen randomly 1000
times to represent the signature of the jth ligand, where nj
was the number of genes comprising the signature for lig-
and j from the compendium of ligand profiles. The moti-
vation for permutation analysis is to determine the
likelihood of obtaining the observed results by random
chance. Between two biologically functioning cells, we
expect some positive correlation due to the activation of
common pathways required for continued cell function.
Therefore, we did not randomize by permuting gene
labels in the patient samples, as doing so would have
resulted in a loss of biologically realistic relationships and
an average correlation of close to zero every time. This
approach results in increased stringency, and thus
increased specificity, when trying to detect statistically
high correlations in that the bar for comparison is set
higher. Conversely, it increases sensitivity in detection of
statistically lower correlations, which facilitates the detec-
tion of dysregulated pathways.
For each ligand that had shown a statistically significant
level of correlation with a disease dataset, we analyzed
degree of correlation as a factor influencing survival using
censored survival data. Cox proportional-hazards analysis
was performed on the full set of patients, using the survival
package [32] in R, version 2.3.1 [33]. In addition, patient
groups were divided into highest, lowest, and medium
level of correlation. Kaplan-Meier survival analysis was
performed on the two extreme tertiles, again using R's sur-
vival package.
Compendia
The Bild et al. dataset was generated from nine replicate
arrays for each of five pathway mutations induced by
recombinant adenoviruses in human primary mammary
epithelial cell cultures (HMECs), as well as GFP treated
HMEC controls [1]. The authors used Affymetrix Human
Genome U133 Plus 2.0 Arrays. Pathway signatures for
positive controls in mouse cancer models were "regener-
ated" from genes with human orthologs.
The Connectivity Map dataset consisted of 564 profiles,
representing 164 small molecule perturbagens applied in
varying concentrations to one or more cell types. Microar-
ray analysis was performed on Affymetrix GeneChip
arrays.
The mouse B cell compendium of gene expression data
from the Alliance for Cell Signaling has been described
[7]. In brief, splenic B cells were purified from mice and
cultured with either a ligand or medium alone for 0.5, 1,
2, or 4 hours. With some exceptions, each ligand/time
point combination was performed in triplicate. RBC-
depleted splenocytes were used as a universal reference for
cDNA hybridization. We used the 4 hour time point for
EPSA analysis, as it best approximated chronic exposure to
a ligand.
Positive controls
As positive controls, we performed correlation analysis on
two datasets using known perturbations of B cells: one in
murine cells, one in human. We first evaluated an inde-
pendent dataset from GEO, GSE1014, with the full set of
genes and with varying portions of the genes removed, to
simulate loss of signal in translation between species and
platform. Dataset GSE1014 consisted of microarray data
from mouse B cells stimulated with 6 of the 33 ligands
from the original training set. RNA derived from treated
cells at the 6 hour time point was hybridized directly with
RNA from untreated cells, without a universal reference.
As a human positive control, we used 4 cases from a study
in which human B cells were stimulated with a combina-
tion of ligands used in the training set [34]. Four separate
experiments involved stimulation with AIG and CD40 forBMC Medical Genomics 2008, 1:51 http://www.biomedcentral.com/1755-8794/1/51
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6 hours, AIG and CD40 for 24 hours, AIG alone for 24
hours, and AIG and IL4 for 24 hours. An additional array
from this dataset provided information for unstimulated
B cells, which we used to calculate the ratio of treated vs.
untreated B cells.
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